MARKET

PRTO

PRTO

Proteon
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.3120
+0.0082
+2.70%
Opening 12:41 12/10 EST
OPEN
0.3189
PREV CLOSE
0.3038
HIGH
0.3189
LOW
0.3101
VOLUME
50.66K
TURNOVER
--
52 WEEK HIGH
3.940
52 WEEK LOW
0.2200
MARKET CAP
6.11M
P/E (TTM)
-0.3242
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PRTO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

PRTO News

  • Rigrodsky & Long, P.A. Files Class Action Suit Against Proteon Therapeutics, Inc.
  • GlobeNewswire.4d ago
  • Moore Kuehn, PLLC Encourages Liberty Property Trust (LPT), Proteon Therapeutics (PRTO), Ra Pharmaceuticals (RARX), Carolina Trust BancShares (CART), and Highlands Bankshares (HLND) Investors to Contact Firm
  • PR Newswire.6d ago
  • Hedge Funds Watching Proteon Therapeutics Inc (PRTO) From Afar
  • Insider Monkey.11/30 03:33
  • SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
  • GlobeNewswire.11/22 18:14

More

Industry

Biotechnology & Medical Research
+0.63%
Pharmaceuticals & Medical Research
+0.67%

Hot Stocks

Name
Price
%Change

About PRTO

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company. The Company is focused on the development of pharmaceuticals to address patients with renal and vascular disease. The Company’s product candidate, vonapanitase, is a recombinant human elastase. The Company is developing vonapanitase to improve vascular access outcomes in patients with chronic kidney disease (CKD), undergoing or planning for hemodialysis.
More

Webull offers Proteon Therapeutics Inc (PRTO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.